ARQT Stock Analysis: Buy, Sell, or Hold?
ARQT - Arcutis Biotherapeutics, Inc. Common Stock
$27.12
-0.62 (-2.24%)
▼
5d:
+4.03%
30d:
+16.75%
90d:
+12.02%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Get Alerted When ARQT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ARQT shows positive signals but monitor for confirmation. Market pricing in 12.6% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ARQT shows positive signals but monitor for confirmation. Market pricing in 12.6% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$56.26
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$34.94
22.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ARQT is currently trading at $27.12, which is considered slightly high relative to its 30-day fair value range of $23.68 to $27.70. From a valuation perspective, the stock is trading at a discount (Forward PE: 23.5) compared to its historical average (35.2). Remarkably, the market is currently pricing in an annual earnings decline of 12.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ARQT is in a strong uptrend. Immediate support is located at $25.25, while resistance sits at $29.84.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.62 (+27.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ARQT is in a strong uptrend. Immediate support is located at $25.25, while resistance sits at $29.84.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.62 (+27.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$23.68 -
$27.70
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 27.7% below Wall St target ($34.62)
Trading Range Analysis
30-Day Trading Range
$23.68 -
$27.70
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$25.25
Resistance Level
$29.84
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.47
Wall Street Target
$34.63
(+27.7%)
Revenue Growth (YoY)
60.1%
Profit Margin
-0.6%
Valuation Discount vs History
-12.6% cheaper
PE vs Historical
23.5 vs 35.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-12.6%
(market-implied from PE analysis)
1-Year Target
$24.41
(-10%)
2-Year Target
$21.97
(-19%)
3-Year Target
$19.77
(-27%)
3-Yr Target (if PE normalizes)
(PE: 23→35)
$29.66
(+9%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.5, Growth: 371.7%)
$91.53
(+238%)
Base:
(SPY PE: 21.8, Growth: 371.7%)
$84.95
(+213%)
Bear:
(PE: 18.5, Growth: 371.7%)
$72.21
(+166%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 23.5 to 35.2
Stabilization Target:
$40.68
(+50.0%)
PE Expansion Potential:
+50.0%
Share & Embed Analysis
Last updated: July 13, 2026 9:29 PM ET
Data refreshes hourly during market hours. Next update: 10:29 PM
Data refreshes hourly during market hours. Next update: 10:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARQT showing a specific setup today?
Insider Activity (6 Months)
1
Buys
14
Sells
Net
INSIDERS SELLING
Recent Transactions
Howard G Welgus
SELL
10000 shares
2026-04-01
Gilbert Ray Cisneros, Jr.
BUY
2026-03-03
Larry Todd Edwards
SELL
3687 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |
Advanced ARQT Option Strategies
Professional options setups generated by AI based on today's ARQT price and gamma walls.
